Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Research Area
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Discover high-quality research tools to investigate GLP-1 mechanisms and next-generation metabolic targets.
OBESITY RESEARCH SOLUTIONSDapagliflozin is an inhibitor of sodium-glucose transporter 2 (SGLT2; IC50s = 1.12 and 3 nM for the human and rat enzymes, respectively).1 It is selective for SGLT2 over SGLT1 (IC50s = 1,391 and 620 nM for the human and rat enzymes, respectively) and human adipocyte glucose transporter (GLUT) activity at 20 µM. Dapagliflozin (0.1 and 1 mg/kg) increases urinary glucose levels in normal and Zucker diabetic rats. It decreases fasting and fed plasma glucose levels in Zucker diabetic rats when administered at doses of 0.01, 0.1, and 1 mg/kg.
WARNING This product is not for human or veterinary use.
1. Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes 57(6), 1723-1729 (2008).